Similar articles for PMID: 12468527

Year	Number of Results
1988	1
1997	1
1998	2
1999	4
2000	5
2001	5
2002	3
2003	8
2004	3
2005	4
2006	2
2007	9
2008	7
2009	2
2010	3
2011	1
2012	2
2013	3
2014	2
2015	3
2016	1
2017	1
2020	2
2021	1
2022	2
2023	1

1

Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.

Laking GR, Price PM. Laking GR, et al. J Nucl Med. 2002 Dec;43(12):1728-9; author reply 1729. J Nucl Med. 2002. PMID: 12468527 Free article. No abstract available.

2

Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.

Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A. Helal BO, et al. J Nucl Med. 2001 Oct;42(10):1464-9. J Nucl Med. 2001. PMID: 11585858 Free article.

3

[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.

Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ. Wang W, et al. J Clin Endocrinol Metab. 1999 Jul;84(7):2291-302. doi: 10.1210/jcem.84.7.5827. J Clin Endocrinol Metab. 1999. PMID: 10404792

4

Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.

Lind P, Kohlfürst S. Lind P, et al. Semin Nucl Med. 2006 Jul;36(3):194-205. doi: 10.1053/j.semnuclmed.2006.03.002. Semin Nucl Med. 2006. PMID: 16762610 Review.

5

Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.

Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Schlüter B, et al. J Nucl Med. 2001 Jan;42(1):71-6. J Nucl Med. 2001. PMID: 11197983 Free article.

6

FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.

Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. Alnafisi NS, et al. J Nucl Med. 2000 Jun;41(6):1010-5. J Nucl Med. 2000. PMID: 10855626 Free article.

7

Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.

Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY. Chung JK, et al. J Nucl Med. 1999 Jun;40(6):986-92. J Nucl Med. 1999. PMID: 10452315 Free article.

8

[Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].

Biscontini G, Possa M, Sara R, Milella M, Rossetti C. Biscontini G, et al. Minerva Endocrinol. 2004 Dec;29(4):151-60. Minerva Endocrinol. 2004. PMID: 15765025 Free article. Review. Italian.

9

Follow-up in patients with differentiated thyroid carcinoma with positive 18F-fluoro-2-deoxy-D-glucose-positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I posttreatment whole body scans.

van Tol KM, Jager PL, Dullaart RP, Links TP. van Tol KM, et al. J Clin Endocrinol Metab. 2000 May;85(5):2082-3. doi: 10.1210/jcem.85.5.6524-2. J Clin Endocrinol Metab. 2000. PMID: 10843201 No abstract available.

10

18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.

Ma C, Wang X, Shao M, Zhao L, Jiawei X, Wu Z, Wang H. Ma C, et al. Q J Nucl Med Mol Imaging. 2015 Jun;59(2):220-7. Epub 2014 May 21. Q J Nucl Med Mol Imaging. 2015. PMID: 24844253

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed